Management

Ulf has been a director of Isofol since 2010 and has been its clinical and regulatory expert. He has a long and successful experience within oncology research and development including leading positions in the United States in Celgene, Takeda, Pfizer and Eli Lily. Ulf has had key roles in the clinical development and market approval of drugs such as Alimta® (pemetrexed), Revlimid® (lenalidomide), Vidaza® (azacitidine) and Abraxane (nab + paclitaxel). In addition, Ulf has participated in several major Due Diligence processes that have resulted in multi-billion acquisitions, including Celgene’s acquisitions of Abraxis and Pharmion.

Position: Chief Executive Officer

Elected: 2019

Year of birth: 1951

Holdings: 233 336 shares*, 250 000 warrants**

Independent in relation to the company and its management: Yes

Independent in relation to larger shareholders: Yes

Tony Gustavsson leads the licensing and commercialization efforts of the company’s lead drug candidate arfolitixorin. Prior to joining Isofol, Mr. Gustavsson served in increasingly senior commercial positions in AstraZeneca and its predecessor companies. During his career Mr. Gustavsson has worked in local, regional and global commercial roles based in Sweden, the UK and the US. Most recently Mr. Gustavsson was the global head of the Pricing and Market Access department responsible for AstraZeneca’s Cardiovascular, Metabolic and Renal portfolio. Prior to this role he was the global Commercial Lead for one of AstraZeneca’s antidiabetics franchises leading the global launch of the products. Mr Gustavsson has an BSc in Business, Administration and Economics from Lund University.

Tony joined Isofol in 2020.

Dr. Roger Tell is responsible for medical and scientific issues at Isofol. Dr. Tell joined Isofol in February 2019 and has served as the Senior Vice President of Clinical Development and Chief Scientific Officer, and as the Chief Medical Officer since August 2019. He joined Isofol from Aprea Therapeutics, where he was Vice President of Clinical Development. Prior to Aprea, he was an International Clinical Project Director at Servier in Suresnes, France. He has an extensive experience as an oncologist as well as an advisor to a number of biopharma companies, including Eli Lilly, Astra Zeneca and Merck Serono. Dr. Tell holds a medical degree and a doctorate in experimental oncology from the Karolinska Institutet in Sweden, and he completed his residency in oncology at the Karolinska University Hospital.

Roger joined Isofol in 2019.

Position: Chief Scientific Officer and Chief Medical Officer

Holdings in Isofol: 0 shares*, 176 300 warrants**

Contact:
E-mail: roger.tell@isofolmedical.com
Phone: (+46) 760 293 911

*Own or related natural or legal person holding shares and other financial instruments in the company. Holdings as of September 30, 2020.
** Isofol Medical AB (publ) warrent program 2018 series 2018/2022 and 2018/2023 . For more information and terms read more under Corporate Governance.

Gustaf is a business-oriented economist with broad financial and operational experience. He is responsible for the company’s financial management and reporting and will play an important role in the company’s continued efforts to develop its investor relations. Gustaf comes must recently from the position of CEO of Elanders Sverige AB, a subsidiary of Elanders AB, listed on Nasdaq Stockholm’s Mid Cap list, and was before that the CFO for the same company. Prior to Elanders, Gustaf worked for Deloitte and Arthur Andersen as an accountant for 17 years and as an authorized accountant for 11 years. During his time as auditor, Gustaf gained broad and profound knowledge in accounting and financial reporting, focusing on IFRS, for larger Swedish and international companies. Gustaf holds a Master of Science in Economics and International Accounting and Auditing from the School of Economics from the University of Gothenburg.

Gustaf joined Isofol in 2017.

Position: Chief Financial Officer

Holdings: 20 206 shares*, 176 300 warrants**

Contact:
E-mail: gustaf.albert@isofolmedical.com
Phone: +(46) 709 168 302